Trial reportBMC infectious diseases2026
The safety and tolerability of oral TDF/FTC as pre-exposure prophylaxis among men who have sex with men in China: a prospective cohort study.
Trial report in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04754139 (A Promotion and Implementation Project of HIV Pre-Exposure Prophylaxis Among High Risk Population), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Promotion and Implementation Project of HIV Pre-Exposure Prophylaxis Among High Risk Population
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundPre-exposure prophylaxis (PrEP) has been demonstrated as an effective strategy for preventing HIV infection. However, multiple barriers contribute to its suboptimal uptake in China, with drug safety being a shared concern for both clinicians and patients. This study aimed to assess the safety and tolerability of oral tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) for PrEP in a real-world setting in China.
methodsAn open-label, prospective cohort study was conducted between September 2021 and September 2024 in Wuhan and Guangzhou, China. PrEP-eligible men who have sex with men (MSM) were enrolled, participants were prescribed TDF/FTC as PrEP and followed up for 12 months. Adverse events (AEs) were self-reported, and participants underwent regular monitoring for HIV, syphilis, liver and kidney function during follow-up.
resultsA total of 1,138 participants enrolled and initiated PrEP, with 1,045 completing at least one follow-up visit. Seven participants were diagnosed with HIV infection, yielding an HIV incidence rate of 0.8 per 100 person-years (95% CI: 0.2-1.4). A total of 62 participants self-reported 106 AEs, the majority of which were grade 1, with no serious AEs observed. Participants reported a significantly higher AE incidence with daily PrEP than on-demand PrEP (14.7 per 100 person-years vs. 9.3 per 100 person-years, P < 0.05). Additionally, 128 episodes of serum creatinine (SCr) and 701 episodes of liver enzyme abnormalities were recorded, and mild elevations in ALT, AST, and SCr were significantly more frequent among participants taking the daily regimen. Significant ALT elevations were observed from the 1st month to the 9th month follow-up, while SCr elevations occurred predominantly in the 1st month.
conclusionsBoth daily and on-demand PrEP regimens with TDF/FTC are safe and well tolerated for the prevention of HIV among Chinese MSM. On-demand PrEP with fewer AEs and comparable effectiveness provides an alternative HIV prevention strategy for Chinese MSM in real-world settings.
trial registrationThe study is registered in Clinical Trial databases in China (ChiCTR2100048981, July 19, 2021) and the US (NCT04754139, February 11, 2021).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.